Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.68 USD | -1.34% | -4.91% | +4.84% |
06-13 | Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease | CI |
05-08 | Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study | MT |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Equities
- ALDX Stock
- Revisions Aldeyra Therapeutics, Inc.